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Cardiovascular disease, the leading cause of death in the United
States and worldwide, accounts for substantial suffering and
healthcarerelated expenditures (1–3). For more than 30 years,
the American Heart Association (AHA) and the American Col-
lege of Cardiology (ACC) have partnered with other organiza-
tions to translate the best available scientiﬁc evidence into
clinical practice guidelines (CPGs) for cardiovascular condi-
tions. These efforts reﬂect a shared vision and responsibility
for using scientiﬁc evidence and the expert clinical opinion
of leaders in the ﬁeld to develop recommendations for health-
care providers. These CPGs, based on systematic methods to
evaluate and classify evidence, have provided the cornerstones
for delivering quality cardiovascular care.CPGs are essential tools for optimizing care for patients
with cardiovascular conditions. Enhancing the utility of
CPGs requires that the development process reﬂect the evo-
lution of relevant foundational domains, such as biomedical
discoveries, public policy, clinical care systems, and epide-
miological knowledge. Dynamic changes in these domains
pose substantial implications for organizations that develop
CPGs. Among these changes is the increasing prevalence
of $2 chronic conditions among individual Americans, esti-
mated to be present in more than one quarter of adults (4).
In the large population of Medicare beneﬁciaries, the
prevalence of persons with multiple chronic conditions is
considerably greater: more than two thirds (68%) have $2
chronic conditions, and 14% have $6 chronic conditions
(5,6).oard of Trustees, the American Heart Association Science Advisory and
rvices in July 2014.
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1852COMORBIDITIES AND CPGs FOR
CARDIOVASCULAR CONDITIONS
CPGs jointly developed by the AHA/ACC are cardiovas-
cular diseasespeciﬁc documents focused on the pre-
vention, diagnosis, and management of conditions such
as ischemic heart disease, heart failure, and atrial ﬁbril-
lation. These CPGs often contain considerations for spe-
cial factors (e.g., older adults) and common problems
affecting pharmacokinetics (e.g., renal impairment). For
example, the 2014 CPG on atrial ﬁbrillation (7) highlights
special considerations for acute myocardial infarction,
pregnancy, hyperthyroidism, and other conditions. With
the exception of the CPGs on atrial ﬁbrillation and
heart failure (7,8), CPGs have not systematically incor-
porated recommendations on how common comorbidities
that accompany a speciﬁc cardiovascular condition
might affect the care and management of patients with
comorbidities.
With progressive growth in the size of the older adult
population and the increased prevalence of comorbidities
in patients with cardiovascular conditions, CPGs need to
address the complex implications of comorbidity for the
care of cardiovascular patients. This issue is particularly
important for some older adults, because clinicians must
select from among treatments on the basis of evidence for
risk and beneﬁt (9). Recognizing this imperative, the
AHA/ACC have taken steps to address comorbidities more
consistently in CPGs, including actions resulting from the
U.S. Department of Health and Human Services initiative
on multiple chronic conditions (10). The centerpiece of
this initiative—a strategic framework on multiple chronic
conditions—explicitly focuses on the need for developers
of CPGs to address chronic conditions (11). Accordingly,
the Department of Health and Human Services and the
Institute of Medicine convened a stakeholder meeting
that included the AHA/ACC to identify core principles for
CPGs in the effective management of people with multi-
ple chronic conditions and related actions that might be
taken by developers of CPGs (12). At the request of the
AHA/ACC, the Centers for Medicare & Medicaid Services
(CMS) provided the data for analysis of the most common
comorbidities in Medicare beneﬁciaries with selected
cardiovascular conditions for potential use in develop-
ment of CPGs.
PREVALENCE OF COMORBIDITIES AMONG
PATIENTS PRESENTING WITH INDEX
CARDIOVASCULAR CONDITIONS
To assess the frequency of comorbidities, the 10 most
common comorbid conditions among Medicare beneﬁ-
ciaries were identiﬁed using CMS administrative enroll-
ment and claims data (13) for 4 index cardiovascularconditions: ischemic heart disease, heart failure, atrial
ﬁbrillation, and stroke. The Medicare population was
limited to beneﬁciaries ‡65 years of age who were
continuously enrolled in Medicare fee-for-service (both
Parts A and B) during 2012. Beneﬁciaries enrolled in
Medicare Advantage during 2012 were excluded because
claims data were unavailable for these beneﬁciaries.
Beneﬁciaries who died during the year were included up
to the date of death.
For each of the 4 index cardiovascular conditions,
comorbidity was determined with the following condi-
tions: acquired hypothyroidism, acute myocardial
infarction, Alzheimer’s disease or dementia, anemia,
arthritis (osteoarthritis and rheumatoid arthritis), asthma,
atrial ﬁbrillation, autism spectrum disorder, benign
prostatic hyperplasia, breast cancer (female and male),
cataract, chronic kidney disease, colon cancer, chronic
obstructive pulmonary disease, depression, diabetes
mellitus, endometrial cancer, glaucoma, heart failure,
hip or pelvic fracture, hyperlipidemia, hypertension,
ischemic heart disease, lung cancer, osteoporosis, pros-
tate cancer, schizophrenia and other psychotic disorders,
or stroke. A Medicare beneﬁciary was considered to have
a chronic condition if the CMS administrative data
included a claim indicating that the beneﬁciary received
service or treatment for the speciﬁc condition. Detailed
information on the identiﬁcation of chronic conditions
is available from the CMS Chronic Conditions Data
Warehouse (13).
Table 1 shows the 10 most common comorbidities
for each index cardiovascular condition for beneﬁciaries
‡65 years of age in 2012 (13). The numbers of Medicare
beneﬁciaries with the 4 index cardiovascular conditions
were 8,678,060 with ischemic heart disease, 4,366,489
with heart failure, 2,556,839 with atrial ﬁbrillation,
and 1,145,719 with stroke. Two conditions that are
major cardiovascular risk factors—hypertension and
hyperlipidemia—constitute the most frequent dyad. Hy-
pertension, hyperlipidemia, and ischemic heart disease
were the 3 most prevalent comorbidities for patients with
heart failure, atrial ﬁbrillation, and stroke, whereas hy-
pertension, hyperlipidemia, and diabetes mellitus were
the most prevalent comorbidities in those with ischemic
heart disease; however, arthritis, anemia, chronic ob-
structive pulmonary disease, and Alzheimer’s disease also
appeared.
Table 2 lists the top 5 most prevalent dyad and triad
comorbidities for beneﬁciaries ‡65 years of age with at
least 2 (for dyads) or 3 (for triads) chronic conditions.
Combinations of high cholesterol, high blood pressure,
and ischemic heart disease were most frequently repre-
sented in the dyads and triads, with diabetes mellitus and
arthritis completing the remaining prevalent combina-
tions (14).
TABLE 1
The 10 Most Common Comorbidities for 4 Index Cardiovascular Conditions: 2012 Data for Medicare
Beneﬁciaries $65 Years of Age (13)
Comorbidity
Ischemic Heart Disease*
(N ¼ 8,678,060)
HF*
(N ¼ 4,366,489)
AF*
(N ¼ 2,556,839)
Stroke*
(N ¼ 1,145,719)
Hypertension 1 (81.3) 1 (85.6) 1 (84.5) 1 (89.0)
Hyperlipidemia 2 (69.1) 3 (62.6) 2 (64.4) 2 (69.9)
Diabetes mellitus 3 (41.7) 5 (47.1) 7 (37.1) 6 (41.5)
Arthritis 4 (40.6) 6 (45.6) 6 (41.7) 5 (44.2)
Anemia 5 (38.7) 4 (51.2) 5 (43.0) 4 (46.8)
HF 6 (36.3) Index 4 (50.9) 7 (37.2)
Ischemic heart disease Index 2 (72.1) 3 (63.5) 3 (58.1)
Chronic kidney disease 7 (30.2) 7 (44.8) 8 (34.4) 8 (35.2)
Cataract 8 (21.6) † 10 (22.6) †
COPD 9 (21.0) 8 (30.9) 9 (23.8) †
AF 10 (18.7) 9 (28.8) Index †
Alzheimer’s disease/dementia † 10 (26.3) † 9 (33.8)
Depression † † † 10 (29.7)
Stroke † † † Index
*Data shown as rank and percentage of persons with index condition who also had a comorbidity. The percentage is included parenthetically when applicable. †Comorbidity was not in
the top 10 for this index condition (13).
AF indicates atrial ﬁbrillation; COPD, chronic obstructive pulmonary disease; and HF, heart failure.
TABLE 2
The 5 Most Prevalent Comorbidities for 2012
Medicare Beneﬁciaries $65 Years of Age With
at Least 2 (Dyads) or 3 (Triads) Chronic
Conditions (14)
Comorbidities Prevalence (%)
Dyads (beneﬁciaries with $2 comorbidities; N¼19,139,696)
High cholesterol and high BP 57.2
High BP and ischemic heart disease 36.8
High BP and arthritis 33.3
High BP and diabetes mellitus 32.7
High cholesterol and ischemic heart disease 31.3
Triads (beneﬁciaries with $3 comorbidities; N¼14,908,988)
High cholesterol, high BP, and ischemic heart disease 35.8
High cholesterol, high BP, and diabetes mellitus 31.7
High cholesterol, high BP, and arthritis 28.8
High BP, diabetes mellitus, and ischemic heart disease 21.5
High BP, arthritis, and ischemic heart disease 20.6
BP indicates blood pressure. Reproduced with permission from the Centers for
Medicare & Medicaid Services (14).
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1853IMPLICATIONS AND FUTURE DIRECTIONS
IN THE DEVELOPMENT OF CPGs
Two general, but important, points emerge from the CMS
data. First, a beneﬁciary with cardiovascular disease but
without at least 1 comorbid chronic condition is the
exception rather than the rule. Second, whereas common
risk factors such as hypertension and hyperlipidemia are
associated with the index cardiovascular conditions, the
index conditions are associated with a constellation of
comorbidities, the pathophysiology of which may be
distinct from the index condition and for which preva-
lence increases with age or other factors.
Organizations that develop CPGs must now consider
comorbidities during the development process for
disease-speciﬁc CPGs. For high-prevalence index condi-
tions, few CPGs address comorbidities (15), and even
fewer provide guidance for patients with speciﬁc combi-
nations of diseases. Managing patients with multiple
conditions is more complex than managing patients with
a single disease, and the presence of multiple conditions
increases challenges for healthcare providers and patients.
Comorbidities may constitute barriers to adherence to
CPGs, and caring for patients with multiple comorbidities
can affect patient safety if recommendations for diagnosis
and treatment in one CPG conﬂict with those for another
condition (16). The complexity of various regimens for
multiple comorbidities adds to the difﬁculty in patient
management and assessment of clinical outcomes (17).
Furthermore, limited attention has been given to the
physical, cognitive, social, psychological, and ﬁnancialimplications of managing comorbidities. Involving pa-
tients in the CPG development process, which the AHA/
ACC recently initiated, is critically important to fully
appreciate patient perspectives (18,19).
Currently, there are important challenges in addressing
common comorbidities in the development and imple-
mentation of CPGs. Patients with comorbidities are often
excluded from clinical trials, limiting the evidence with
which to make generalizable recommendations (20–22).
This concern is explicitly addressed in the Department of
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emphasizes the need for external validation of clinical
and drug approval trials by ensuring that persons with
multiple comorbid conditions are not excluded unneces-
sarily (11). In support of this objective, the U.S. Food and
Drug Administration now instructs that a regular part of
its assessment of clinical trials incorporate a closer ex-
amination of the populations to be included in such trials
and presumes that drug developers include patients with
multiple comorbid conditions (23). The increasing use of
electronic health records and clinical registries would also
allow a longitudinal evaluation of the management stra-
tegies and clinical outcomes of patients with cardiovas-
cular disease and comorbidities, which often is not
afforded by randomized clinical trials. Other challenges to
addressing comorbidities in CPGs are the number of
comorbidities to be considered and those that may be
underreported, such as obesity, depression, signiﬁcant
cognitive impairment, and frailty, several of which
become increasingly common with age and affect patientmanagement and outcome. Thus, given the current lack
of trial evidence and the complexity of treating patients
with common cardiovascular comorbidities, CPGs may, in
certain instances, need to be more nuanced to account
for clinical judgment and acknowledge the role of
individualized, patient-centered decision making in
implementation.
In the future, the AHA/ACC CPGs will explicitly discuss
the applicability and quality of recommendations for
the most frequent combinations of comorbidities that
accompany cardiovascular conditions. An important
step in this direction is the collaboration between the
AHA/ACC and the Department of Health and Human
Services that includes development of comorbidity data
for selected cardiovascular conditions that, in turn, can be
included and addressed in CPGs such as the most recent
guidelines on atrial ﬁbrillation and heart failure (7,8). The
AHA/ACC aim to partner with various organizations to
determine how best to highlight and address the complex
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